Newron Receives Fifth Tranche From Financing Agreement With European Investment Bank (Eib)
Round Type
Debt Financing
MilanBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 5 under its financing agreement with the European Investment Bank (EIB) that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria. The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment plan for Europe. Tranche 5 consists of EUR 7.5 million and will primarily be used to support the Company’s development programs in diseases of the central nervous system
Fundz sees it the moment Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.